LENZ · CIK 0001815776
What LENZ Therapeutics, Inc. told the SEC could break it.
LENZ Therapeutics' disclosures all converge on a single product. It has no other candidates in its development pipeline, so its success depends entirely on commercializing VIZZ — and it owns no manufacturing, relying on third-party manufacturers for commercial supply with some raw materials, including the aceclidine hydrochloride API, coming from a single-source supplier. As a still pre-profitability company it has incurred significant net losses, with a $227.1 million accumulated deficit at year-end and operations funded mainly through equity, so profitability hinges on VIZZ's commercial success, which is itself exposed to Inflation Reduction Act Medicare drug-price negotiation and pricing pressure.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Other disclosures
- single-product dependence on VIZZ (no other pipeline candidates)high
LENZ has no other product candidates in development, so its entire success depends on the commercialization of VIZZ.
“We do not currently have other product candidates in our development pipeline, and our success depends entirely on VIZZ.”
SEC filing →As of 2026
Sole-source dependency
- single-source API supplier; full reliance on third-party CMOs for VIZZhigh
LENZ has no internal manufacturing and depends on third-party manufacturers for commercial VIZZ supply, with some raw materials (aceclidine hydrochloride API) from a single-source supplier — a concentrated supply chain for its only product.
“We relied on third-party manufacturers for the production of our product for our clinical trials and are relying and expect to continue to rely on third-party manufacturers for the commercial supply of VIZZ. Furthermore, the raw materials for our product are sourced, in some cases, from a single-source supplier.”
SEC filing →As of 2026
Liquidity & debt
- accumulated deficit / reliance on equity financing as commercialization rampsmedium
LENZ has incurred significant net losses since formation (accumulated deficit $227.1M at year-end 2025) and has funded operations mainly through equity issuance and its reverse-merger, with profitability dependent on VIZZ's commercial success.
“we have incurred significant net losses since the company's formation and we have funded our operations primarily from the sale and issuance of redeemable convertible preferred stock, common stock, and the Merger.”
SEC filing →As of 2026
Regulatory & policy
- IRA Medicare drug-price negotiation and pricing pressuremedium
The Inflation Reduction Act lets the federal government negotiate maximum fair prices for certain single-source Medicare drugs and imposes inflation rebates and penalties, creating pricing and reimbursement risk for VIZZ.
“allowing the federal government to negotiate a maximum fair price for certain high-priced single source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
CORXEL Pharmaceuticals
“tiered, escalating royalties in the range of 5% to 15% on net sales of Products in Greater China by CORXEL, its affiliates and sublicensees, and (iii) tiered, deescalating royalties in the range of 15% to 5% of sublicensing income received by CORXEL prior to the regulatory approval of the first Product in Greater China.”
Cited →Lunatus
“are eligible to receive regulatory and commercial milestone payments and a per unit fee for each unit sold to Lunatus for distribution in the Middle East, pending regulatory approval.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch